Decreased serum osteoprotegerin levels in patients with cardiac syndrome X

Journal of Endocrinological Investigation

Volumn 27, Issue 9, 2004, Pages 839-843

  Altun, A ^a,b   Ugur Altun, B ^a   Tatli, E ^a  

^a TRAKYA UNIVERSITY   (Turkey)

^b Kocasinan Mah   (Turkey)

Author keywords

Cardiac syndrome X; Microangiopathy; Obesity; Osteoprotegerin

Indexed keywords

BIOLOGICAL MARKER; OSTEOPROTEGERIN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; HUMAN; KRUSKAL WALLIS TEST; LEAN BODY WEIGHT; MALE; MICROANGIOPATHY; OBESITY; PATHOGENESIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RANK SUM TEST; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; SYNDROME X; TREADMILL EXERCISE;

EID: 14544289680     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346278     Document Type: Article

References (31)

1. Hofbauer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001, 280: 334-9.
2. Malyankar UM, Scatena M, Suchland KL, Yuri TJ, Clark EA, Giachelli CM. Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem 2000, 275: 20959-62.
3. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273: 14363-7.
4. Scatena M, Giachelli C. The αvβ3 integrin, NF-κB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med 2002, 12: 83-8.
5. Vazquez-Rey E, Kaski JC. Cardiovascular syndrome X and endothelial dysfunction. Rev Esp Cardiol 2003, 56: 181-92.
6. Adamopoulos S, Rosano GM, Ponikowski P, et al. Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. Am J Cardiol 1998, 82: 862-8.
7. Altun A, Erdogan O, Tatli E, Ugur-Altun B, Durmus-Altun G, Ozbay G. Increased P wave dispersion: A new finding in patients with syndrome X. Can J Cardiol 2002, 18: 1207-10.
8. Altun A, Yaprak M, Aktoz M, Vardar A, Ugur-Altun B, Ozbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002, 327: 143-5.
9. Bund SJ, Tweddel A, Hutton I, Heagerty AM. Small artery structural alterations of patients with microvascular angina (syndrome X). Clin Sci (Lond) 1996, 91: 739-43.
10. Suziki H, Takeyama Y, Koba S, Suwa Y, Katagari T. Small vessel pathology and coronary hemodynamics in patients with microvascular angina. Int J Cardiol 1994, 43: 139-50.
11. Chen JW, Hsu NW, Ting CT, Lin SJ, Chang MS. Differential coronary hemodynamics and left ventricular contractility in patients with syndrome X. Int J Cardiol 2000, 75: 49-57.
12. Takeuchi M, Kuroiwa A. Alteration of coronary flow velocity during spontaneous angina in a patient with microvascular angina. Catheter Cardiovasc Interv 2000, 50: 63-7.
13. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002, 346: 948-53.
14. Pedrinelli R, Spessot M, Lorenzoni R, et al. Forearm vasodilatory capacity in patients with syndrome X. J Hypertens 1989, 7: 92-3.
15. Antonios TF, Kaski JC, Hasan KM, Brown SJ, Siger DR. Rarefaction of skin capillaries in patients with anginal chest pain and normal coronary arteriograms. Eur Heart J 2001, 22: 1144-8.
16. Bellamy MF, Goodfellow J, Tweddel AC, Dunstan FD, Lewis MJ, Henderson AH. Syndrome X and endothelial dysfunction. Cardiovasc Res 1998, 40: 410-7.
17. Takeuchi M, Nohtomi Y, Kuroiwa A. Paradoxal increase in coronary flow velocity after termination acetylcholine infusion is a marker of impaired vasodilatation at coronary microvessels in patients with angina and normal coronary arteries. Catheter Cardiovasc Interv 1999, 48: 170-7.
18. Lin CP, Lin WT, Leu HB, Wu TC, Chen JW. Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. Int J Cardiol 2003, 89: 53-62.
19. Rosen SD, Uren NG, Kaski JC, Tousoulis D, Davies GJ, Camici PG. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation 1994, 90: 50-60.
20. Cannon RO 3rd, Peden DB, Berkebile C, Schenke WH, Kaliner MA, Epstein SE. Airway hyperresponsiveness in patients with microvascular angina. Evidence for a diffuse disorder of smooth muscle responsiveness. Circulation 1990, 82: 2011-7.
21. Khosla S, Arrighi HM, Melton LJ, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002, 13: 394-9.
22. Kudlacek S, Scheider B, Woloszczuk W, Pietschmann P, Willvonseder R, for the Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in healthy adult population. Bone 2003, 32: 681-6.
23. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22: 549-53.
24. Sattler AM, Schoppet M, Schaefer A Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004, 74: 103-6.
25. Colin Osdoby P, Rothe I, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001, 276: 20659-72.
26. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits arterial calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001, 21: 1610-6.
27. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106: 1192-4.
28. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003, 88: 1024-8.
29. Montorsi P, Agostoni PG, Annoni L, Vincenzi P, Guazzi MD. Cardiopulmonary exercise testing in syndrome X. Am Heart J 1993, 125: 711-7.
30. Sole MJ, Drobac M, Schwartz L, Hussain MN, Vaughan-Neil EF. The extraction of circulating catecholamines by the lungs in normal man and in patients with pulmonary hypertension. Circulation 1979, 60: 160-3.
31. Brandstrom H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A. A single nucleotide polymorphism in the promoter region of human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 2002, 293: 13-7.